Ikena Oncology to Participate in September 2021 Virtual Investor Conferences

Rhea-AI Summary

Ikena Oncology (Nasdaq: IKNA) announced participation in the virtual Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Management will engage in a fireside chat on September 10, 2021, at 10:15 am EST during the Morgan Stanley conference. Webcasts are accessible for replay through the company's website, available for 90 days post-event. Ikena focuses on developing novel cancer therapies targeting key signaling pathways.

BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways, today announced that management will participate in the virtual Morgan Stanley 19^th Annual Global Healthcare Conference taking place on September 9-15, 2021, and the H.C. Wainwright 23^rd Annual Global Investment Conference, taking place on September 13-15, 2021.

Details are as follows:

Conference: Morgan Stanley 19^th Annual Global Healthcare Conference
Fireside Chat: Friday, September 10, 2021, 10:15am EST; live and available for replay        
Webcast Link

Conference: H.C. Wainwright 23^rd Annual Global Investment Conference
Date: Monday, September 13, 2021; available for replay        
Webcast Link

The presentation webcasts can be accessed by visiting the Investors & Media section of the company’s website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the live event.

About Ikena Oncology

Ikena Oncology is focused on developing novel therapies targeting key signaling pathways that drive the formation and spread of cancer. Ikena is advancing multiple programs that target tumor markers as well as programs targeting the tumor microenvironment. The Company’s lead program, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway, a pathway that can drive formation and increase survival of tumors and also drives development of resistance to multiple existing therapies. Additional programs include an ERK5 inhibitor program targeting the KRAS signaling pathway and several programs targeting the tumor microenvironment and immune signals, two of which are being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on targeting genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.

Media Contact:
Gwen Schanker
LifeSci Communications
gschanker@lifescicomms.com

Investor Contact:
Rebecca Cohen
Ikena Oncology
rcohen@ikenaoncology.com

 

FAQ

What events is Ikena Oncology participating in September 2021?

Ikena Oncology is participating in the Morgan Stanley 19th Annual Global Healthcare Conference from September 9-15, 2021, and the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021.

When will Ikena Oncology's fireside chat take place?

Ikena Oncology's fireside chat is scheduled for September 10, 2021, at 10:15 am EST during the Morgan Stanley conference.

How can I access Ikena Oncology's conference webcasts?

The webcasts for Ikena Oncology's conferences can be accessed through the Investors & Media section of their website and will be available for replay for 90 days after the events.

What is the focus of Ikena Oncology's research?

Ikena Oncology focuses on developing novel cancer therapies that target key signaling pathways involved in cancer formation and spread.

What is the ticker symbol for Ikena Oncology?

The ticker symbol for Ikena Oncology is IKNA.